Investment Rating - The report maintains a "Buy" rating for China Pacific Insurance (02328) [2] Core Views - The underwriting performance is strong, with a significant increase in underwriting profit by 44.6% year-on-year [5] - The company’s net profit for the first half of 2025 increased by 32.3% year-on-year to CNY 24.455 billion, with a second quarter net profit growth of 4.1% year-on-year to CNY 13.143 billion [5] - The combined ratio (COR) improved by 1.4 percentage points year-on-year to 94.8%, aligning with expectations [5] - The company has increased its stock allocation by 2 percentage points since the beginning of the year, indicating a positive shift in investment strategy [5] Financial Data and Profit Forecast - The company’s total investment assets reached CNY 711.48 billion, a 5.2% increase from the end of 2024 [5] - The report projects net profits for 2025-2027 to be CNY 36.852 billion, CNY 40.899 billion, and CNY 47.124 billion respectively, up from previous forecasts [6] - The projected earnings per share (EPS) for 2025 is CNY 1.66, with a price-to-earnings (P/E) ratio of 10.25 [7] Business Segments - In the auto insurance segment, premium income increased by 3.4% year-on-year to CNY 144.065 billion, with underwriting profit rising by 67.7% year-on-year to CNY 8.726 billion [8] - The non-auto insurance segment also saw growth, with premium income up by 3.8% year-on-year to CNY 179.217 billion, and underwriting profit increasing by 13.0% year-on-year to CNY 4.289 billion [8]

香港中华煤气 (3 HK) 2025 年秋季策略会速递— 延伸业务挖潜，气源结构优化 证券研究报告 | 华泰研究 | | 动态点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | | 2025 年 | 8 月 28 日│中国香港 | 燃气及分销 | 目标价(港币): | 7.63 | 8 月 27 日香港中华煤气出席了我们组织的 2025 年秋季策略会，会上公司重 点围绕延伸业务、气源结构、香港市场优势及内地业务展开交流。延伸业务 引入外部投资强化 B2C 运营与数字化建设，香港主导利润贡献，内地潜力 待挖掘；内地城市燃气气源以三桶油为主，计划提升非常规/现货气占比以 优化成本；香港煤气呈垄断格局且气价成本可转嫁，内地工商业用气增长承 压但延伸业务空间大。维持"买入"评级。 延伸业务引入战略投资，明确"先扩客再跨域"路径 管理层表示，为强化延伸业务（燃气灶具、保险等 B2C 业务）运营能力， 引入元禾辰坤（苏州国资控股）与方圆资本，前者提供地方资源协同，后者 凭借消费品领域经验助力数字化（如物联网 LP 平台）与售后服务完善。目 前该业务利润高度依赖香港（ ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6][22] Core Insights - The company has shown strong performance in the high-end domestic beauty market, with significant revenue growth and brand momentum [6][10] - The company reported a revenue of 2.59 billion RMB in H1 2025, representing a year-on-year increase of 31%, and a net profit of 670 million RMB, up 36% year-on-year [6][10] - The gross margin for H1 2025 was 84.2%, with a net profit margin of 25.9%, indicating effective cost control [6][10] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 2,886 million RMB - 2024: 3,885 million RMB - 2025E: 5,173 million RMB - 2026E: 6,852 million RMB - 2027E: 8,533 million RMB - Year-on-year growth rates for revenue are projected at 58% for 2023, 35% for 2024, and gradually decreasing to 25% by 2027 [5][13] - Net profit forecasts are as follows: - 2023: 662 million RMB - 2024: 881 million RMB - 2025E: 1,184 million RMB - 2026E: 1,542 million RMB - 2027E: 1,953 million RMB - The projected PE ratios are 64.7 for 2023, decreasing to 22.5 by 2027 [5][13] Segment Performance - The company experienced double-digit growth in both color cosmetics and skincare, with significant contributions from new product launches [6] - In H1 2025, color cosmetics revenue reached 1.42 billion RMB (up 31.1% YoY), while skincare revenue was 1.09 billion RMB (up 33.4% YoY) [6] - The fragrance segment also showed promising growth, with revenue of 11.41 million RMB, while the makeup training segment saw a decline of 5.9% [6] Channel Performance - The company has effectively released its potential across all channels, with offline revenue of 1.22 billion RMB (up 26.6% YoY) and online revenue of 1.297 billion RMB (up 39% YoY) [6] - The number of members reached 19 million, with a repurchase rate of 26.8%, indicating strong customer loyalty [6] Research and Development - The company is focused on innovation and international expansion, with new product launches planned and a research center set to support growth [6] - The company aims to penetrate the European and Asia-Pacific markets with localized teams and high-end channels [6] Brand Positioning - The company is positioned as a leading domestic beauty brand, capitalizing on the high-end color cosmetics market with a strong emphasis on unique aesthetics and product innovation [6]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][20]. Core Insights - The company achieved a 43% year-on-year increase in net profit attributable to shareholders for the first half of 2025, with total revenue reaching 148.7 billion yuan, a 39.3% increase [1][8]. - The company is focusing on improving operational quality in Southeast Asia while continuing to expand its store presence in domestic markets, with a total of 53,014 stores by mid-2025 [1][10]. - The subsidiary brand, Lucky Coffee, is entering a growth phase, with over 7,800 stores and significant new product launches contributing to revenue growth [3][16]. Financial Performance - For the first half of 2025, the company reported a gross margin of 31.6%, with a net profit margin of 18.1%, reflecting effective cost control and a decrease in the tax rate [3][12]. - The company plans to increase its adjusted net profit forecasts for 2025-2027 to 60.3 billion, 74.5 billion, and 92.2 billion yuan, respectively, indicating a positive outlook for future earnings [3][16]. - The projected earnings per share for 2025 is 15.88 yuan, with a price-to-earnings ratio of 26.5 [4][17]. Store Expansion and Market Strategy - The company added 7,721 franchise stores in the first half of 2025, with a net increase of 6,534 stores, demonstrating strong franchise growth [1][10]. - The geographical distribution of stores shows a focus on mainland China, with 48,281 stores, while also exploring opportunities in Central Asia and the Americas [2][10]. - The company is seeing a faster growth rate in lower-tier cities, with 57.6% of its stores located in tier-three and below cities [2][10].

康方生物 (9926 HK) 港股通 营收高增，HARMONi-A OS 显著获益 | 华泰研究 | | | 中报点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2025 年 | 8 月 | 28 日│中国香港 | 生物医药 | 目标价(港币): | 205.69 | 8 月 26 日公司披露 1H25 中报，明确依沃西单抗在 HARMONi-A 研究中获 得 OS 统计学和临床获益显著。商业化方面，1H25 收入 14.1 亿元 （+37.8%yoy），其中产品销售 14.0 亿元（+49.2%yoy），净亏损 5.9 亿 元（含投资损失 1.6 亿元），在手现金 65.9 亿元。公司业绩增长逻辑清晰： 1）依沃西单抗在 OS 获益支撑下，BIC 地位筑牢，医保赋能下增长动力充 沛；2）两大核心品种全面推动海外临床，进军全球市场。维持"买入"。 证券研究报告 依沃西单抗：HARMONi-A 斩获 OS 显著，全球拓展有望加速 依沃西单抗在联合化疗对照化疗治疗 EGFR-TKI 耐药 NSCLC 的国内 HARMONi-A 研究中取得 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 23.74 [6][7]. Core Views - The company reported a revenue of HKD 415.7 million and a net profit attributable to shareholders of HKD 20.5 million for the first half of 2025, representing a year-on-year decline of 6.9% and 16.4% respectively. The liquid milk business continues to face challenges, while diversified businesses such as ice cream and overseas operations show growth potential [1][2][4]. Revenue and Profitability - The revenue breakdown for the first half of 2025 shows liquid milk at HKD 321.9 million (down 11.2%), ice cream at HKD 38.8 million (up 15.0%), milk powder at HKD 16.8 million (up 2.5%), and cheese at HKD 23.7 million (up 12.3%) [2]. - Gross profit margin increased by 1.5 percentage points to 41.7%, while the net profit margin decreased by 0.6 percentage points to 4.9% due to inventory impairment and losses from joint ventures [3]. Future Outlook - The company anticipates a recovery in liquid milk demand, particularly during the Mid-Autumn Festival and National Day holidays, which are seen as critical observation periods. The ice cream business has returned to positive growth, and profitability in milk powder and cheese is expected to improve [1][4]. Earnings Forecast and Valuation - Revenue forecasts for 2025-2027 have been adjusted downwards to HKD 842.7 billion, HKD 864.3 billion, and HKD 883.3 billion, reflecting a decrease of 5%, 4%, and 4% respectively. The expected EPS for the same period is projected at HKD 1.08, HKD 1.45, and HKD 1.58 [4][10].

Investment Rating - The report maintains an "Overweight" rating for the company [11] Core Insights - The company reported a revenue of 23.19 billion RMB for H1 2025, a year-on-year increase of 10%, while the net profit attributable to shareholders decreased by 31% to 1.0 billion RMB [1][2] - The core net profit was 1.57 billion RMB, down 15% year-on-year, primarily due to increased operational costs and a decline in profit margins [2][3] - The company has significantly increased its dividend payout ratio for 2025 to 60% of core net profit, which is an increase of 27 percentage points from 2024, resulting in an estimated dividend yield of 8.0% [4] Revenue and Profitability - The company's core business revenue grew at a double-digit rate, driven by the expansion of its property management services, particularly in the "Three Supplies and One Industry" segment, which saw a revenue increase of 68% [2] - The overall gross margin decreased by 2.6 percentage points to 18.5%, influenced by higher management expenses and increased investments in service quality [2][3] - The company expects to maintain high single-digit growth in core business revenue and profit for the full year, despite increased uncertainty in profit margins [2] Cash Flow and Dividend Policy - The operating cash flow for H1 2025 was negative 880 million RMB, a decline from a positive 270 million RMB in the same period last year, primarily due to increased upfront investments and a decrease in prepayment activities [3] - The company plans to enhance shareholder returns through a combination of cash dividends, share buybacks, and other measures [4] Earnings Forecast and Valuation - The earnings per share (EPS) estimates for 2025-2027 have been adjusted downwards to 0.81 RMB, reflecting a decrease of 11%-19% from previous estimates [5] - The target price for the company is set at 7.10 HKD, based on an adjusted price-to-earnings (P/E) ratio of 8 times for 2025 [5][7]

Investment Rating - The report upgrades the investment rating to "Accumulate" [6][4] Core Insights - The company reported a revenue of 3.89 billion, a year-on-year increase of 5.5%, and a net profit attributable to the parent company of 180 million, up 40.5% year-on-year [1] - The infant formula business saw a decline in domestic sales but significant growth in overseas markets, particularly in goat milk powder, which achieved a revenue increase of 65.7% [1][2] - The company maintains its international market strategy, with goat milk powder expected to continue driving growth, supported by potential improvements in domestic demand due to changing birth policies [1][3] Revenue Breakdown - For the first half of 2025, the revenue from infant formula was 2.83 billion, down 3.8% year-on-year, while cheese and other products saw increases of 51.6% and 7.0%, respectively [2] - Goat milk powder revenue was 1.86 billion, up 3.1%, while cow milk powder revenue decreased by 14.9% [2] - The company achieved a revenue of 2.58 billion in China, down 10.7%, but saw increases in Europe (67.1%), the Middle East (49.4%), and the Americas (67.4%) [2] Profitability Metrics - The gross margin decreased by 1.5 percentage points to 41.9%, with goat milk powder and cow milk powder margins at 55.1% and 52.3%, respectively [3] - The net profit margin increased by 0.7 percentage points to 4.6%, supported by effective cost control measures [3] Earnings Forecast and Valuation - The earnings per share (EPS) estimates for 2025-2027 are adjusted to 0.18, 0.20, and 0.22 RMB, reflecting increases of 13%, 10%, and 7% respectively [4] - The target price is set at 2.97 HKD, based on a 15x price-to-earnings ratio for 2025 [4][7]

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Insights - The company reported a revenue of 499 million RMB for 1H25, representing an 812% year-over-year increase, driven by strong sales of Supacizumab in the AD field and unique indications in the nasal area [1][2] - The company plans to participate in the 2025 medical insurance negotiations, which is expected to enhance drug accessibility [1] - The early pipeline shows significant global potential, with CMG901 expected to report results in 2026 and CM512 anticipated to release AD clinical data in 2H25 [1][4] Summary by Sections Sales Performance - Supacizumab sales reached approximately 169 million RMB in 1H25, with expectations for continued growth due to its efficacy advantages over competitors and the upcoming allergy season [2] - The company is preparing to launch an injection pen formulation, which is expected to enhance convenience for patients [2] Early Pipeline Development - CM512 is positioned as a potential treatment for multiple indications, including AD and asthma, with ongoing clinical trials showing promise [3] - The company has clear upcoming milestones for CMG901, with a global Phase III trial for gastric cancer expected to report results in 2026 [4] Financial Health - The company reported a net loss of 78.8 million RMB in 1H25, a 77% reduction in losses year-over-year, with cash reserves of approximately 2.796 billion RMB [5] - The company plans to invest around 300 million RMB in capital expenditures for capacity expansion [5] Profitability Forecast - The revenue forecast for 2025 is adjusted to 727 million RMB, with net profit estimates for 2025 and 2026 at -742 million RMB and -604 million RMB, respectively [6][12] - The target price based on DCF valuation is set at 90.89 HKD, reflecting an increase from the previous estimate of 56.05 HKD [6][12]

证券研究报告 中国东方教育 (667 HK) 港股通 上调全年盈利预测，维持"买入" 考虑到公司新招生强劲，规模效应和严格控费下利润率快速提升，我们上调 25-27 年经调整净利润至 8.08/10.36/12.99 亿元（上调 26%/34%/39%）， 考虑到 25 年已过半，我们切换到 26 年估值，考虑到公司利润弹性大，给 予 20x 26E PE（可比公司 Wind 一致预期均值 13.67x），得到目标价 10.30 港元（前值：6.47 港元，对应 20x 25E PE），维持"买入"评级。 风险提示：在校生人数增长不及我们预期；区域中心建设进展缓慢或效益不 及规划预期；公办职校分流及竞争加剧。 利润弹性如期兑现，上调全年预期 2025 年 8 月 28 日│中国香港 职业教育 公司公布 25H1 业绩：收入 21.86 亿元，yoy+10.2%；净利润 4.03 亿元， yoy+48.4%，符合业绩预告（yoy+45%~50%）；经调整净利润 4.16 亿元， yoy+49.5%。利润的增长主要得益于新招生的增长以及高效的运营及成本费 用控制。公司积极适配市场需求，持续优化专业结构和补足学历教 ...